Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivjoa in acute vulvovaginal candidiasis
NCT01891331Phase 2Completed
- Sponsor
- Viamet Pharmaceuticals
- Start
- Aug 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oteseconazole in vulvovaginal candidiasis (VVC), sponsored by Viamet Pharmaceuticals. Started Aug 2013; status: completed.
02
Drugs
oteseconazole
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT01891331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01891331.